Raymond James Financial
CRVS icon

Raymond James Financial’s Corvus Pharmaceuticals CRVS Stock Holding History

Raymond James Financial’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Sell
99,012
-871
-0.9% -$12.1K ﹤0.01% 3717
2026
Q1 		$1.46M Sell
99,883
-21,274
-18% -$340K ﹤0.01% 3590
2025
Q4 		$933K Sell
121,157
-3,339
-3% -$26.3K ﹤0.01% 3824
2025
Q3 		$918K Hold
124,496
– – ﹤0.01% 3737
2025
Q2 		$498K Buy
124,496
+16,379
+15% +$59.6K ﹤0.01% 4006
2025
Q1 		$344K Sell
108,117
-872
-0.8% -$4.11K ﹤0.01% 4136
2024
Q4 		$583K Buy
+108,989
New +$814K ﹤0.01% 3806

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Raymond James Financial's CRVS Position: Q2 2026 in Review

Raymond James Financial reduced its Corvus Pharmaceuticals (CRVS) stake by 0.87% in Q2 2026, selling an estimated $12.1K and leaving 99,012 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3717.

Raymond James Financial first reported a position in CRVS in Q4 2024 and has held it in 7 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Raymond James Financial held 99,012 shares of Corvus Pharmaceuticals worth $1.48M as of Q2 2026.
  • Raymond James Financial sold 871 Corvus Pharmaceuticals shares in Q2 2026, an estimated $12.1K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3717 holding.
  • Raymond James Financial first reported a position in Corvus Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.